The Scots investment firm backs science, engineering, and technology companies that have the aim of addressing societal and environmental challenges.

Eos’ investment strategy focuses on early-stage equity investments across the key areas of disease diagnosis, prevention, and treatment; energy security, climate change, and pollution; food and water security; and sustainability of industrial processes and infrastructure.

The funding from British Business Investments will be allocated to invest alongside Eos’ Angel Syndicate and EIS Innovation Fund.

Andrew McNeill, Managing Partner at Eos, said the following on the announcement: “The British Business Investments commitment will enhance our ability to back some of Scotland’s most exciting early stage science and technology companies.

“We are already bringing this relationship to life, with recent investments into Bioliberty and Dxcover, and are in conversations about a strong pipeline of opportunities.”

Further, Andrew Durkie, Partner at Eos, said: “We are pleased to be working with British Business Investments, to have their support, and to become one the latest Scottish investment firms on its Regional Angels Programme.

“The initiative enables Eos to extend our support for companies targeting global issues, and having a positive impact on the world.”

Judith Hartley, CEO, British Business Investments, also commented: “The Regional Angels Programme plays a vital role in developing the early-stage funding ecosystem across the UK Nations and Regions, bringing together finance, business experience and skills to support the development of high-growth smaller businesses.

“By investing alongside Eos’s Angel Syndicate and EIS Innovation Fund, this £10m commitment from British Business Investments will support early-stage science and technology companies in Scotland and across the UK.”

Recommended

• Cloud First 2023 | Your Guide to Data Protection Regulations
• Online Safety Bill: Researchers Call for Social Media Data Access
• Chair of UK Gov’s Foundation Model Taskforce Announced

In April this year, DIGIT reported on the news that the Scots investment firm had expanded its portfolio and added to its leadership team as it sought to accelerate growth.

Investee companies are now at a total of 19, with the latest investment being in Edinburgh-based Bioliberty, the robotic rehabilitation specialist.

The investment firm’s latest hire, Jill Arnold — who was former Head of SIS Ventures — joined as Investor Relations Director.

Eos’s portfolio includes Carcinotech, Chromacity, Cumulus Oncology, Dxcover, Nth, Green Bioactives, ENOUGH, GM Flow, ILC Therapeutics, Naturbeads, Novosound, Penrhos Bio, RAB Microfluidics, Rooser, Waire Health, Wobble Genomics, and Xelect, as well as the aforementioned Bioliberty.